Advances in the management of psoriatic arthritis

被引:56
|
作者
Olivieri, Ignazio [1 ]
D'Angelo, Salvatore [1 ]
Palazzi, Carlo [2 ]
Padula, Angela [1 ]
机构
[1] San Carlo Hosp Potenza, Rheumatol Dept Lucania, I-85100 Potenza, Italy
[2] Madonna Grazie Hosp Matera, Rheumatol Dept Lucania, I-75100 Matera, Italy
关键词
ORAL PHOSPHODIESTERASE-4 INHIBITOR; COMPOSITE DISEASE-ACTIVITY; SEVERE PLAQUE PSORIASIS; JANUS KINASE INHIBITOR; DOUBLE-BLIND; CONTROLLED-TRIAL; PERIPHERAL SPONDYLOARTHRITIS; CLASSIFICATION CRITERIA; SCREENING QUESTIONNAIRE; ANKYLOSING-SPONDYLITIS;
D O I
10.1038/nrrheum.2014.106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriatic arthritis (PsA), which affects musculoskeletal structures, skin and nails, is a heterogeneous chronic inflammatory disease with a wide clinical spectrum and variable course. Patients with PsA are more likely than healthy individuals to have metabolic syndrome or cardiovascular disease. To include these comorbidities, 'psoriatic disease' has been suggested as an umbrella term. The management of PsA has changed tremendously over the past decade owing to early diagnosis and improvement in treatment strategies, including, early referral from dermatologists and primary-care physicians to rheumatologists, early initiation of therapy, treating to the target of remission or low disease activity, and advances in pharmacological therapy. Outcome assessment is also improving, because of validated instruments for clinical disease manifestations. The commercialization of TNF blockers, including adalimumab, etanercept, golimumab and infliximab, is representative of a revolution in the treatment of PsA. A new anti-TNF agent, certolizumab pegol, and a fully human monoclonal antibody against IL-12 and IL-23, ustekinumab, are approved for the treatment of active PsA. The efficacy of ustekinumab suggests that inhibiting the type 17 T helper pathway might be an alternative to blocking TNF. PsA management must now use improved measures to predict patient outcomes and define remission, and develop better-targeted therapies.
引用
收藏
页码:531 / 542
页数:12
相关论文
共 50 条
  • [31] Immunomodulating drugs in the management of psoriatic arthritis
    Jackson C.G.
    American Journal of Clinical Dermatology, 2001, 2 (6) : 367 - 375
  • [32] Recent genetic advances in innate immunity of psoriatic arthritis
    Hile, Grace
    Kahlenberg, J. Michelle
    Gudjonsson, Johann E.
    CLINICAL IMMUNOLOGY, 2020, 214
  • [33] PSORIATIC-ARTHRITIS - RECENT ADVANCES IN PATHOGENESIS AND TREATMENT
    GLADMAN, DD
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1992, 18 (01) : 247 - 256
  • [34] Updated therapies for the management of Psoriatic Arthritis
    Toussi, Atrin
    Maverakis, Natalia
    Le, Stephanie T.
    Sarkar, Soumajyoti
    Raychaudhuri, Smriti K.
    Raychaudhuri, Siba P.
    CLINICAL IMMUNOLOGY, 2020, 220
  • [35] Psoriatic arthritis: advances in pharmacotherapy based on molecular target
    Scarpa, Raffaele
    Costa, Luisa
    Atteno, Mariangela
    Del Puente, Antonio
    Caso, Francesco
    Moll, John M. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (17) : 2311 - 2313
  • [36] Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity
    Caso, Francesco
    Costa, Luisa
    Del Puente, Antonio
    Scarpa, Raffaele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (01) : 1 - 2
  • [37] Lifestyle Modification for the Management of Psoriatic Arthritis
    Deboisblanc, Charles
    Hynes, Marijane
    Mbuyi, Nadine
    AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2023,
  • [38] Role of Methotrexate in the Management of Psoriatic Arthritis
    Musaab Elmamoun
    Vinod Chandran
    Drugs, 2018, 78 : 611 - 619
  • [39] Recommendations for the management and treatment of psoriatic arthritis
    Carneiro, Sueli
    Azevedo, Valderilio Feijo
    Bonfiglioli, Rubens
    Ranza, Roberto
    Goncalves, Celio Roberto
    Keiserman, Mauro
    Meirelles, Eduardo de Souza
    Pinheiro, Marcelo de Medeiros
    Ximenes, Antonio Carlos
    Bernardo, Wanderley
    Sampaio-Barros, Percival Degrava
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2013, 53 (03) : 227 - 241
  • [40] Pharmacotherapeutic management of psoriatic disease: addressing psoriatic arthritis and cutaneous manifestations
    Yi, Robin C.
    Gantz, Hannah Y.
    Shah, Shailey C.
    Moran, Shannon K.
    Klionsky, Yael E.
    Feldman, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (16) : 2203 - 2212